Table of Content

Strategic Imperatives
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Senolytics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Scope and Segmentation
Research Context and Scope of Analysis
Segmentation
Growth Opportunity Analysis
Growth Drivers
Growth Restraints
Introduction to Senescence and Senolytics
The Need for Senotherapeutics
Senolytics Are Emerging as a Promising Class of Senotherapeutics
Benefits of Senolytics over Other Senotherapeutics
Senolytic Drug Development Timeline
Senolytics—A Novel Approach to Healthcare, Presents Interesting Opportunities and Challenges
Successes, Opportunities, and Failures in Senolytic Drug Discovery
Promising R&D Prospects in Senolytics
Technology Snapshot
Things to Know about Senolytic Drug Development
Approaches to Target Sncs Increase R&D Opportunities and Success Possibilities
Targets, Drugs, and Modalities under Investigation to Develop Senolytic Drugs
Anti-apoptotic Pathways Are a Highly Explored Area for Senolytics
Targeting Anti-apoptotic Pathways Is a Common Approach to Senolytic Drugs
Tackling Newer Targets Is an Emerging Approach
Therapies Targeting Various Physiologies and Pathways
Small Molecule Senolytics
Biologics under Development for Senolytics
Cell and Gene Therapies under Development for Senolytics
Approaches to Improve the Senolytic Drug Development Process
Players in the Senolytic Drug Development Field
Natural Products Can Potentially Translate to Senolytics
Naturally Derived Senolytics and Commercial Developments
Opportunities and Recent Advancements in Naturally Derived Senolytics
Continuous Innovations Will Shape the Senolytic Drug Development Industry during the Next 5 Years
Outlook for Senolytic Drug Development
Technology Enablers Bolstering Senolytics Development
Senolytic Drug Technology Enablers
Emerging Technologies for Senolytic Drug Development and Diagnostics
Biomarkers Play a Vital Role in the Senotherapeutic Industry
Efforts to Discover a Universal SNC Biomarker
AI-assisted Advances in Drug Discovery and Diagnostics
Stakeholder Ecosystem
Financial Growth, M&As, Partnership Trends, and New Entrants Are Evident in the Young Field of Senolytics
A Conducive Funding Environment, an Active R&D Space, and the Significant Contribution of AI Drive Senolytic Drug Development
Completed M&As and Proposed Mergers to Look Forward to in 2023
Partnerships in Senolytic Drug Discovery and Development Skew Toward AI
Partnerships in Senolytic Drug Discovery and Development Skew Toward AI (continued)
Drug and Technology Licensing and IPOs by Senolytic Developing Companies Will Increase
Spin-off Companies Developing Senolytic Drugs Are on the Increase
Conducive Grants and Research Funding Support Senotherapeutics
Funding Analysis in the Senolytic Drug Development Industry
Growth Opportunity Universe
Growth Opportunity 1: Growing Involvement of Large Pharma Companies
Growth Opportunity 1: Growing Involvement of Large Pharma Companies (continued)
Growth Opportunity 2: Development of New Biomarkers to Aid in Drug Discovery
Growth Opportunity 2: Development of New Biomarkers to Aid in Drug Discovery (continued)
Growth Opportunity 3: Convergence Opportunities Between Drug Development Companies
Growth Opportunity 3: Convergence Opportunities Between Drug Development Companies (continued)
Next Steps
Legal Disclaimer